ESMO Plenary Nov 2023 - ESMO Virtual Plenaries: Nov 2023
Nov 03 - Nov 03, 2023 | LuganoSwitzerland
LARVOL is not affiliated with ESMO Virtual Plenaries: Nov 2023 and all trademarks, logos, and brand names are property of their respective owners
Condition
Product
MOA
Trial Name/ID
Showing 1 abstracts linked to Trials
Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)